Aflibercept for Diabetic Macular Edema In Real-life Practice in GREece

Sponsor
University of Athens
Study ID
NCT05683912
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
45 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Aflibercept — DRUG
    Intravitreal aflibercept as used in the routice clinical practice

Study Details

ADMIRE was a prospective, observational cohort study of patients with diabetic macular edema (DME). Efficacy was assessed by change in best-corrected visual acuity (BCVA) and central retinal thickness (CRT) from baseline to months 12, 24 and 36 after treatment with intravitreal aflibercept in treatment-naïve patients and previously treated patients. Safety was evaluated by recording any patients-reported events.

Key Dates

Start date
Sep 1, 2019
Status verified
Dec 2022
Primary completion
Sep 1, 2021
Completion
Dec 15, 2022

Study Design

Enrollment
100 participants (actual)

Primary Outcome Measure

Change in best-corrected visual acuity [ Time Frame: 12 months ]

Related Studies